Aviado · Research
Longevity Daily
Thursday, November 12, 2026
Listen
Today's Brief
Today's sharpest story is a Nature study of 2.8 million people — the largest Alzheimer's genetic analysis ever — implicating the brain's own immune cells as a central driver of disease. If you're spending money on NMN supplements, stop and read our second pick first: independent lab testing found 64% of top-selling Amazon products contain less than 1% of their labeled dose. We also cover VITAL-H, the first clinical trial pairing GLP-1 and SGLT2 drugs against aging itself, a rapamycin-class lifespan result from a novel mechanism, and Aviado's breakdown of how GABA actually reshapes your sleep architecture.
10 stories7 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Largest Alzheimer's Genetic Study Ever — 2.8 Million People — Points to the Brain's Immune Cells
Led by Vrije Universiteit Amsterdam and published in Nature, this is the largest genetic association study of Alzheimer's ever conducted, drawing on data from 2.8 million participants. The findings reveal that microglia — the brain's resident immune cells — and several specific neuron types play a more central role in Alzheimer's biology than previously understood, giving drug developers the most precise genetic roadmap yet for targeting neuroinflammation. This doesn't change what you can do today, but it reshapes how the next generation of treatments will be prioritized: therapies aimed at calming the brain's immune response are likely to gain significant new momentum. Consider this the clearest scientific mandate so far for the neuroinflammation thesis that researchers like Dale Bredesen have long argued.
Read more →A Vibrating Bed Prototype Helps Flush Toxic Alzheimer's Proteins From the Brain, Scans Confirm
Researchers at the University of Oulu used a specially engineered vibrating bed to mechanically stimulate the glymphatic drainage system — the brain's waste-clearance network that becomes most active during sleep. Brain MRI scans confirmed the technique physically dislodged amyloid proteins and flushed them into major veins, the first real-world human evidence that this pathway can be activated non-pharmacologically. The device isn't commercially available, but the science strengthens the case that supporting glymphatic flow — whether through deep sleep, future devices, or therapies targeting CSF drainage — is a valid anti-dementia strategy worth taking seriously.
Read more →Estrogen Exposure Linked to Healthier Brain Blood Vessels and Less Age-Related Damage in Women
A study reported by Healio finds that women with greater lifetime estrogen exposure — from reproductive history and exogenous hormone therapy — showed measurably less damage to small brain blood vessels, a key early driver of cognitive decline. The associations extended across multiple markers of both vascular and neurodegenerative brain aging, suggesting the protective effect is broad rather than pathway-specific. These are observational associations, not proof of causation, but they add meaningful weight to the clinical debate about hormone therapy's role in cognitive aging — particularly for women weighing HRT decisions in midlife.
Read more →Supplements & Compounds
64% of Top-Selling NMN Supplements on Amazon Contain Almost None of What's on the Label
ISO-accredited lab testing by ChromaDex found that 14 of 22 top-selling NMN products on Amazon contained less than 1% of their labeled dose — and three contained no detectable NMN at all. The findings are being highlighted by supplement brand Element 5, which is now publishing batch-level third-party test reports for its own product as a differentiator. If you're spending $50–100 per month on NMN expecting meaningful NAD+ support, this data is a mandate to verify certificates of analysis from an independent lab before trusting any label claim.
Read more →An Over-the-Counter Mineral Supplement Clears Senescent Cells and Extends Mouse Lifespan
A new study covered by Lifespan.io shows that vanadyl sulfate — an inexpensive, food-derived mineral sold OTC at most supplement retailers — acts as a senolytic, selectively clearing senescent 'zombie' cells and producing measurable healthspan and lifespan gains in male mice even when treatment started late in life. The late-start design matters: it suggests the benefit isn't dependent on early intervention, making it more relevant to adult readers. This remains mouse data requiring human validation, but vanadyl sulfate's established safety record and OTC status could accelerate its path to human trials compared to novel pharmaceutical senolytics.
Read more →GABA for Deep Sleep: What the Science Actually Says About Your Sleep Architecture
Aviado Research reviews 18 randomized controlled trials and finds consistent evidence that GABA supplementation reliably increases slow-wave (deep) sleep and decreases REM sleep — a genuine, measurable shift in sleep architecture rather than generalized sedation. If you track sleep with an Oura ring or similar device, typical doses of 100–300 mg may produce a detectable deep-sleep increase in your nightly data. The key caveat: the precise mechanism by which orally consumed GABA crosses the blood-brain barrier remains debated, leaving some mechanistic uncertainty beneath an otherwise robust clinical signal.
Read the full Aviado analysis →Research & Papers
New Trial Will Test GLP-1 and SGLT2 Drugs Together — Against Aging Itself — in Healthy Adults
The University of Texas Health Science Center at San Antonio has registered VITAL-H (Validation and Intervention Testing for Aging, Longevity and Healthspan), combining two FDA-approved drug classes — GLP-1 receptor agonists and SGLT2 inhibitors — to test whether their combination can jointly slow biological aging in healthy older adults. Each class has individual longevity signals, and combining them could prove additive by hitting metabolic and cellular pathways simultaneously. This is a registration, not results yet, but its design to test aging directly in a healthy population — not a disease cohort — marks an important shift in how longevity medicine is being formally studied.
Read more →A Novel Drug Target Delivers Rapamycin-Class Lifespan Gains in Mice — With a Completely Different Mechanism
Research covered by Fight Aging! shows that inhibiting asparagine endopeptidase — an enzyme that becomes increasingly problematic in aging tissues — extended median mouse lifespan by 17% (from 24 to 28 months) when treatment began at 18 months, the rough equivalent of human midlife. This puts it in the same ballpark as late-life rapamycin results, an exceptionally high bar. The mechanism is entirely distinct from mTOR inhibition, raising the theoretical possibility of stacking it with rapamycin for additive effects — though that remains speculative, and all results are in mice awaiting human validation.
Read more →Lifestyle & Nutrition
Tinnitus Isn't the Dementia Risk — the Hearing Loss Behind It Is, and That Changes What You Should Do
Physician Jay Motley MD untangles a persistent confound: in the best-controlled studies, tinnitus's association with dementia risk largely disappears once researchers account for hearing loss and age, which typically accompany the ringing. The durable, well-replicated finding is that hearing loss itself is one of the largest modifiable dementia risk factors we have — and treating it with hearing aids shows genuine promise, though Motley rates the trial evidence three stars due to mixed results so far. If you've been dismissing hearing decline as a minor inconvenience, this is the clearest argument for why that calculation may be costing you cognitive reserve.
Read more →Industry & Policy
Longevity Biotech's Ambitions Are Outrunning FDA Endpoints and Investment Frameworks
Pharmaceutical Technology's analysis identifies the sector's core structural bottleneck: without validated clinical endpoints the FDA will accept for 'aging' or 'healthspan,' companies can't run approval-track trials the same way they do for established diseases. A federally funded initiative called PROSPR is working with the FDA to build those endpoints, but progress is slow. The practical takeaway for biotech watchers: companies in this space are advised to target specific age-related diseases first, then reposition toward broader longevity claims as regulatory frameworks mature — a sequencing strategy that shapes where smart money is currently going.
Read more →